Outlook Therapeutics, Inc. (OTLK) competitors & alternatives
Health Care · NASDAQ
Outlook Therapeutics, Inc. (OTLK)'s top competitors and alternatives — its most similar public companies — include Regeneron Pharmaceuticals (REGN), NOVARTIS AG (NVS), KODIAK SCIENCES INC (KOD), GLAUKOS CORP (GKOS), EYEPOINT INC (EYPT), HARROW INC (HROW), OCULAR THERAPEUTIX INC (OCUL), 4D MOLECULAR THERAPEUTICS INC (FDMT), OCUGEN INC (OCGN), OPUS GENETICS INC (IRD), MEIRAGTX HOLDINGS PLC (MGTX) and TARSUS PHARMACEUTICALS INC (TARS). These are Outlook Therapeutics, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top OTLK competitors & alternatives
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$153.08 (as of 2026-07-22) · market cap $229.2B
-
KODIAK SCIENCES INCKODHealth Care
Kodiak Sciences is a pre-commercial retina biotech pioneering ultra-long-acting intravitreal biologics via its ABC platform, with lead anti-VEGF Zenkuda…
$41.92 (as of 2026-07-22) · market cap $2.6B
-
GLAUKOS CORPGKOSHealth Care
Glaukos is a specialized ophthalmic company transforming eye care through innovative Micro-Invasive Glaucoma Surgery devices and proprietary sustained-release…
$152.86 (as of 2026-07-22) · market cap $8.9B
-
EYEPOINT INCEYPTHealth Care
EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular…
$12.66 (as of 2026-07-22) · market cap $1.1B
-
HARROW INCHROWHealth Care
A specialty ophthalmic pharmaceuticals company developing and commercializing a broad portfolio of branded drugs and biosimilars for front and back-of-eye…
$42.83 (as of 2026-07-22) · market cap $1.6B
-
OCULAR THERAPEUTIX INCOCULHealth Care
Ocular Therapeutix is a biopharmaceutical company leveraging proprietary bioresorbable hydrogel technology to deliver retinal therapies, with AXPAXLI…
$8.59 (as of 2026-07-22) · market cap $2.0B
-
4D MOLECULAR THERAPEUTICS INCFDMTHealth Care
4D Molecular Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for ophthalmic and respiratory diseases using its proprietary…
$10.96 (as of 2026-07-22) · market cap $573M
-
OCUGEN INCOCGNHealth Care
A gene therapy company developing novel modifier gene therapies to treat inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and…
$1.29 (as of 2026-07-22) · market cap $440M
-
OPUS GENETICS INCIRDHealth Care
Clinical-stage biopharmaceutical company developing AAV-based gene therapies to restore vision in patients with inherited retinal diseases.
$3.05 (as of 2026-07-22) · market cap $252M
-
MEIRAGTX HOLDINGS PLCMGTXHealth Care
A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and…
$12.16 (as of 2026-07-22) · market cap $1.1B
-
TARSUS PHARMACEUTICALS INCTARSHealth Care
Tarsus Pharmaceuticals commercializes XDEMVY, the first FDA-approved treatment for Demodex blepharitis, with a pipeline of lotilaner-based therapies for ocular…
$57.58 (as of 2026-07-22) · market cap $2.5B
Not quite? Describe exactly what you want →
Peers are Outlook Therapeutics, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Outlook Therapeutics, Inc. (OTLK).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.